ProShare Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-12,370
| Closed | -$19.7K | – | 2199 |
|
|
2025
Q1 | $19.7K | Sell |
12,370
-3,724
| -23% | -$5.92K | ﹤0.01% | 2038 |
|
|
2024
Q4 | $48.8K | Sell |
16,094
-13,904
| -46% | -$42.1K | ﹤0.01% | 2179 |
|
|
2024
Q3 | $110K | Buy |
29,998
+17,814
| +146% | +$65.6K | ﹤0.01% | 1863 |
|
|
2024
Q2 | $49.8K | Sell |
12,184
-3,252
| -21% | -$13.3K | ﹤0.01% | 1751 |
|
|
2024
Q1 | $243K | Buy |
15,436
+1,274
| +9% | +$20.1K | ﹤0.01% | 1552 |
|
|
2023
Q4 | $215K | Buy |
14,162
+1,979
| +16% | +$30K | ﹤0.01% | 1598 |
|
|
2023
Q3 | $244K | Buy |
12,183
+1,946
| +19% | +$39K | ﹤0.01% | 1339 |
|
|
2023
Q2 | $289K | Buy |
+10,237
| New | +$289K | ﹤0.01% | 1299 |
|
|
2023
Q1 | – | Sell |
-10,759
| Closed | -$217K | – | 1925 |
|
|
2022
Q4 | $217K | Buy |
10,759
+791
| +8% | +$15.9K | ﹤0.01% | 1443 |
|
|
2022
Q3 | $217K | Buy |
9,968
+1,230
| +14% | +$26.8K | ﹤0.01% | 1356 |
|
|
2022
Q2 | $245K | Sell |
8,738
-2,818
| -24% | -$79K | ﹤0.01% | 1337 |
|
|
2022
Q1 | $534K | Sell |
11,556
-2,794
| -19% | -$129K | ﹤0.01% | 1248 |
|
|
2021
Q4 | $1.21M | Buy |
14,350
+132
| +0.9% | +$11.1K | ﹤0.01% | 937 |
|
|
2021
Q3 | $947K | Sell |
14,218
-1,830
| -11% | -$122K | ﹤0.01% | 926 |
|
|
2021
Q2 | $854K | Buy |
16,048
+2,745
| +21% | +$146K | ﹤0.01% | 1124 |
|
|
2021
Q1 | $577K | Buy |
13,303
+665
| +5% | +$28.8K | ﹤0.01% | 1340 |
|
|
2020
Q4 | $656K | Buy |
+12,638
| New | +$656K | ﹤0.01% | 1097 |
|